Compounds > tybamate
Page last updated: 2024-11-05

tybamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tybamate is a non-benzodiazepine anxiolytic medication. It is structurally related to meprobamate, but has a different pharmacological profile. Tybamate is a GABAergic drug that acts as a positive allosteric modulator of the GABAA receptor, similar to benzodiazepines. It is also thought to have some anticholinergic properties. Tybamate was initially developed in the 1950s for the treatment of anxiety disorders. However, it is no longer widely prescribed in many countries due to concerns about its potential for abuse and dependence. It is still available in some countries, but its use is generally limited to patients who are not able to tolerate other anxiolytics. Tybamate is typically well-tolerated, but common side effects include drowsiness, dizziness, and headache. Research on tybamate has been limited in recent years, but it continues to be studied as a potential treatment for anxiety disorders and other conditions. Some researchers are exploring the possibility that tybamate could be useful in the treatment of chronic pain, insomnia, and alcohol withdrawal syndrome.'

tybamate: major descriptor (65-84); on-line search CARBAMATES (65-84); Index Medicus search TYBAMATE (65-84) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20266
CHEMBL ID2104816
CHEBI ID135133
SCHEMBL ID78046
MeSH IDM0262806

Synonyms (70)

Synonym
solacin
benvil
2-(hydroxymethyl)-2-methylpentyl butylcarbamate carbamate
solacen
tibamax
tibamato
carbamic acid, ester with 2-(hydroxymethyl)-2-methylpentyl butylcarbamate
tybamate
n-butyl-2-methyl-2-propyl-1,3-propanediol dicarbamate
idalene
nsc-172126
carbamic acid,3-propanediol butylcarbamate
4268-36-4
nsc172126
carbamic acid, 2-(hydroxymethyl)-2-methylpentyl ester carbamate
2-methyl-2-propyl-1,3-propanediol butylcarbamate carbamate
tybatran
effisax
2-methyl-2-propyltrimethylene butylcarbamate carbamate
nospan
carbamic acid, ester with 2-(hydroxymethyl)-2-methylpentyl carbamate
2-(hydroxymethyl)-2-(methylpentyl) butylcarbamate carbamate
1, 2-methyl-2-propyl-, butylcarbamate carbamate
depran
tibamate
w 713
reposan
wln: zvo1x3&1&1ovm4
carbamic acid, butyl-, 2-[[(aminocarbonyl)oxy]methyl]-2-methylpentyl ester
2-[(carbamoyloxy)methyl]-2-methylpentyl butylcarbamate
carbamic acid, butyl-, 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
n-n-butyl-2-methyl-2-propyl-1,3-propanediol dicarbamate
carbamate of 2-(hydroxymethyl)-2-methylpentyl ester of butylcarbamic acid
hsdb 3410
carbamic acid, ester with 2-methyl-2-propyl-1,3-propanediol butylcarbamate
nsc 172126
einecs 224-254-9
brn 1970468
butylcarbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
1,3-propanediol, 2-methyl-2-propyl-, butylcarbamate carbamate
tybamatum [inn-latin]
tibamato [inn-spanish]
carbamic acid, butyl-, 2-(hydroxymethyl)-2-methylpentyl ester, carbamate
carbamic acid, butyl-, 2-(hydroxymethyl)-2-methylpentyl ester carbamate (ester)
carbamic acid, ester with 2-methyl-2-propyl-1, 3-propanediol butylcarbamate
carbamic acid, butyl-, 2-(hydroxymethyl)-2-methylpentyl ester carbamate
[2-(carbamoyloxymethyl)-2-methyl-pentyl] n-butylcarbamate
carbamic acid, butyl-, ester with 2-(hydroxymethyl)-2-methylpentyl carbamate
carbamic acid, butyl-, {2-[[(aminocarbonyl)oxy]methyl]-2-methylpentyl} ester
1, 3-propanediol, 2-methyl-2-propyl-, butylcarbamate carbamate
tybamate (usan/inn)
solacen (tn)
D06260
CHEBI:135133
[2-(carbamoyloxymethyl)-2-methylpentyl] n-butylcarbamate
tybamatum
tybamate [usan:inn:ban:nf]
unii-3875lll8m8
3875lll8m8 ,
w-713
CHEMBL2104816
tybamate [inn]
tybamate [who-dd]
tybamate [mi]
tybamate [usan]
tybamate [hsdb]
SCHEMBL78046
PRBORDFJHHAISJ-UHFFFAOYSA-N
DTXSID7023728
Q7859691
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.14 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		3.5590amino-acid anion
carisoprodol
Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.		1.9610carbamate estermuscle relaxant
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		2.6330organic molecular entity
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		1.9610barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
methyl carbamate
methyl carbamate : A carbamate ester resulting from the formal condensation of the carboxy group of carbamic acid with methanol.		1.9410carbamate ester
ConditionIndicatedRelationship StrengthStudiesTrials
Psychoses
[description not available]		01.9310
Psychotic Disorders
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)		01.9310
Anxiety Neuroses
[description not available]		02.6330
Neuroses
[description not available]		02.6330
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		07.8540
Anxiety Disorders
Persistent and disabling ANXIETY.		02.6330
Neurotic Disorders
Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.		02.6330
Absence Seizure
[description not available]		01.9410
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9410
Brain Damage, Chronic
A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.		02.3420
Brain Disorders
[description not available]		01.9410
Cerebral Arteriosclerosis
[description not available]		01.9410
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.		01.9410
Intracranial Arteriosclerosis
Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.		01.9410
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		01.9410